Back to Agenda
Advancing Pediatric Drug Development in Asia through Real-World Evidence and Regulatory Innovation
Session Chair(s)
Yongjing Zhang, PHD
Senior Director, Global Epidemiology
Johnson & Johnson, China
This session will showcase how Real-World Evidence (RWE) supports pediatric drug development in Asian countries, share US and EU perspectives, and highlight innovations in regulatory strategies, policies, and methodologies to enhance regulatory-grade pediatric RWE.
Learning Objective : Demonstrate emerging trends in the use of RWE in regulatory decision-making in Asia, with real examples of leveraging RWE to accelerate pediatric drug development, highlighting innovative approaches and successful outcomes; Discuss challenges and strategies for high-quality pediatric RWE and explore regulatory frameworks for RWE evaluation through innovative cross-organizational collaborations.
Speaker(s)
Panelist
Shaoqing Ni
Zhejiang University, China
Attending Pharmacist , Director
Panelist
Ju-Young Shin, PHD
School of Pharmacy, Sungkyunkwan University, Korea, Republic of
Professor
Panelist
Representative Invited
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Have an account?